[ALS disease modeling and drug screening using patient-specific iPS cells]

Area of Science:

• Neurodegenerative disease research
• Stem cell biology
• Molecular genetics

Context:

• Amyotrophic lateral sclerosis (ALS) involves motor neuron loss and progressive paralysis.
• Cytosolic aggregates of Tar DNA-binding protein-43 (TDP-43) are a hallmark of ALS.
• Over twenty TDP-43 mutations are linked to ALS, yet effective cures remain elusive.

Purpose:

• To identify drug-screening targets for ALS by characterizing cellular phenotypes in patient-specific motor neurons.
• To utilize patient-derived induced pluripotent stem cells (iPSCs) for modeling ALS.

Summary:

• Patient-specific iPSCs were generated from fibroblasts of ALS patients with mutant TDP-43.
• These iPSCs were differentiated into motor neurons (MNs) exhibiting disease-specific phenotypes like TDP-43 aggregation and neurite shortening.
• Treatment with anacardic acid ameliorated these observed ALS-related cellular defects.

Impact:

• Patient-specific iPSCs offer a valuable platform for drug screening and understanding ALS pathogenesis.
• This study highlights potential therapeutic strategies targeting TDP-43 related cellular dysfunction in ALS.
• The findings pave the way for developing personalized medicine approaches for ALS treatment.